Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials

Oliver Löwenstein, Petra Leyendecker, Eberhard A Lux, Mark Blagden, Karen H Simpson, Michael Hopp, Björn Bosse, Karen Reimer, Oliver Löwenstein, Petra Leyendecker, Eberhard A Lux, Mark Blagden, Karen H Simpson, Michael Hopp, Björn Bosse, Karen Reimer

Abstract

Background: Two randomised 12-week, double-blind, parallel-group, multicenter studies comparing oxycodone PR/naloxone PR and oxycodone PR alone on symptoms of opioid-induced bowel dysfunction in patients with moderate/severe non-malignant pain have been conducted.

Methods: These studies were prospectively designed to be pooled and the primary outcome measure of the pooled data analysis was to demonstrate non-inferiority in 12-week analgesic efficacy of oxycodone PR/naloxone PR versus oxycodone PR alone. Patients with opioid-induced constipation were switched to oxycodone PR and then randomised to fixed doses of oxycodone PR/naloxone PR (n = 292) or oxycodone PR (n = 295) for 12 weeks (20-80 mg/day).

Results: No statistically significant differences in analgesic efficacy were observed for the two treatments (p = 0.3197; non-inferiority p < 0.0001; 95% CI -0.07, 0.23) and there was no statistically significant difference in frequency of analgesic rescue medication use. Improvements in Bowel Function Index score were observed for oxycodone PR/naloxone PR by Week 1 and at every subsequent time point (-15.1; p < 0.0001; 95% CI -17.3, -13.0). AE incidence was similar for both groups (61.0% and 57.3% of patients with oxycodone PR/naloxone PR and oxycodone PR alone, respectively).

Conclusions: Results of this pooled analysis confirm that oxycodone PR/naloxone PR provides effective analgesia and suggest that oxycodone PR/naloxone PR improves bowel function without compromising analgesic efficacy.

Trial registration numbers: ClinicalTrials.gov identifier: NCT00412100 and NCT00412152.

Figures

Figure 1
Figure 1
Study design. PR = prolonged-release.
Figure 2
Figure 2
Patient disposition. PR = prolonged-release
Figure 3
Figure 3
Mean Bowel Function Index score over time (full analysis population; last observation carried forward analysis).

References

    1. Ventafridda V, Saita L, Ripamonti C, De Conno F. WHO guidelines for the use of analgesics in cancer pain. Int J Tissue React. 1985;7:93–96.
    1. Coluzzi F, Pappagallo M. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol. 2005;71:425–433.
    1. Coluzzi F, Mattia C. Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol. 2005;71:451–460.
    1. Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, Kaiko RF, Buckley BJ, Reder RF. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain. 1998;2:239–249. doi: 10.1016/S1090-3801(98)90020-9.
    1. Kalso E. Oxycodone. J Pain Symptom Manage. 2005;29:S47–S56. doi: 10.1016/j.jpainsymman.2005.01.010.
    1. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003;60:927–934.
    1. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology. 1998;50:1837–1841.
    1. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105:71–78. doi: 10.1016/S0304-3959(03)00160-X.
    1. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63:649–671. doi: 10.2165/00003495-200363070-00003.
    1. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182:11S–18S. doi: 10.1016/S0002-9610(01)00782-6.
    1. Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician. 2007;10:479–491.
    1. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1) Pain Med. 2009;10:35–42. doi: 10.1111/j.1526-4637.2008.00495.x.
    1. Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manag. 2002;24:71–90. doi: 10.1016/S0885-3924(02)00424-4.
    1. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10:135–44. doi: 10.1177/026921639601000208.
    1. Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain. 2000;84:105–109. doi: 10.1016/S0304-3959(99)00185-2.
    1. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002;23:48–53. doi: 10.1016/S0885-3924(01)00369-4.
    1. Latasch L, Zimmermann M, Eberhardt B, Jurna I. Treatment of morphine-induced constipation with oral naloxone. Anaesthesist. 1997;46:191–194. doi: 10.1007/s001010050390.
    1. Meissner W, Leyendecker P, Hopp M, Bosse B, Nichols T, Reimer K. Long-term efficacy and safety of oxycodone and naloxone in a prolonged-release fixed combination tablet in patients with moderate to severe chronic pain. WIP, World Institute of Pain, New York. 2009. Abstract number: A-118-0027-00784.
    1. Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K, Ruckes C, Weber S, Grothe B, Fleischer W, Reimer K. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9:1144–1154. doi: 10.1016/j.jpain.2008.06.014.
    1. Smith K, Hopp M, Mundin G, Leyendecker P, Bailey P, Grothe B, Uhl R, Reimer K. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Clin Ther. 2008;30:2051–2068. doi: 10.1016/j.clinthera.2008.11.008.
    1. Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13:56–64. doi: 10.1016/j.ejpain.2008.06.012.
    1. Sander-Kiesling A, Leyendecker P, Hopp M, Tarau L, Lejcko J, Meissner W, Sevcik P, Hakl M, Hrib R, Uhl R, Dürr H, Reimer K. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract. 2010;64:763–774. doi: 10.1111/j.1742-1241.2010.02360.x.
    1. Nadstawek J, Leyendecker P, Hopp M, Wirz S, Ruckes C, Fleischer W, Reimer K. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract. 2008;62:1159–1167. doi: 10.1111/j.1742-1241.2008.01820.x.
    1. Nolte T. Prolonged-release oxycodone/naloxone is effective and safe in clinical use. Pall Med. 2008;22(Suppl):399–565. doi: 10.1177/0269216308091582. Poster 275.
    1. Clemens KE, Quednau I, Klaschik E. Bowel function during therapy with a combination of oxycodone/naloxone prolonged-release tablets in generic patients. 11th EAPC Congress, Vienna. 2009. Poster number F317.
    1. Lux EA, Leyendecker P, Kremers W, Bosse B, Hopp M, Reimer K. Efficacy and safety of oxycodone and naloxone in a prolonged release fixed combination tablet in elderly patients (> 65 years) with moderate to severe chronic pain. 19th IAGG Congress, Paris. 2009. Abstract number PB7 475.
    1. Löwenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R, Bond S, Kremers W, Nichols T, Krain B, Reimer K. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain - a randomised controlled trial. Expert Opin Pharmacother. 2009;10:531–543. doi: 10.1517/14656560902796798.
    1. Simpson K, Leyendecker P, Hopp M, Müller-Lissner S, Löwenstein O, De Andrés J, Troy Ferrarons J, Ruckes C, Krain B, Olway H, Nichols T, Kremers W, Reimer K. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24:3503–3512. doi: 10.1185/03007990802584454.
    1. Rentz AM, Ren Y, Müller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid induced constipation. J Med Economics. 2009;12:371–383. doi: 10.3111/13696990903430481.
    1. Ware J. SF-36 Health Survey Manual & Interpretation Guide. Boston: Nimrod Press; 1993.
    1. Ware J, Kosinski M, Dewey JE. How to score version 2 of the SF-36 Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.
    1. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12. doi: 10.1186/1477-7525-2-12.
    1. World-Medical-Association-Declaration-of-Helsinki. Ethical principles for medical research involving human subjects. 2002.
    1. International Conference on Harmonization (ICH) Guidelines on Good Clinical Practice. 1997.
    1. European Parliament and Council of the European Union. Clinical Trials Directive 2001/20/EC. Official Journal of the European Communities. 2001;121:34–44.
    1. Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut. 1999;45(Suppl II):II1–6. doi: 10.1136/gut.45.2008.ii1.
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129–138.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe